- Passionate scientist with a strong background in pre-clinical translational research & entrepreneurship.
- Pro-active problem-solver with a critical mindset and eye for detail who creates value.
- Accessible, to-the-point mentor who leads by example, collaboration and communication.
- Seasoned writer and presenter with a strong global academic and corporate network.
Bio: Kevin Hollevoet has a degree in Bioengineering (2008, Ghent University, Belgium), a PhD in Medical Sciences (2011, Ghent University), and a postgraduate in Innovation and Entrepreneurship (2017, University of Leuven, Belgium). During his PhD, he managed a Belgian multi-center clinical trial that provided lasting insights on the application of several blood protein markers in the clinical management of mesothelioma. In 2011, Dr. Hollevoet joined the NCI (Bethesda, MD) for a two-year postdoc on immunotoxins (antibody-toxin conjugates). His pre-clinical findings on anti-mesothelin immunotoxins in pancreatic cancer contributed to initiating clinical trials. In 2013, Dr. Hollevoet joined the University of Leuven (KU Leuven), where he currently heads the Antibody Gene Transfer Program at the Laboratory for Therapeutic and Diagnostic Antibodies. This young research branch is dedicated to advancing nucleotide-based antibody therapy in different disease areas, including (immuno-)oncology, infectious diseases and CNS. Dr. Hollevoet is also spearheading an associated spinoff route and acts as Associate Editor for the Journal of Translational Medicine.
Since April 2017
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science. https://translational-medicine.biomedcentral.com/
Group Leader - Antibody Gene Transfer Program
Since June 2016
Built and currently head a pre-clinical program dedicated to gene-based antibody therapy in (immune-)oncology, infectious diseases and CNS (team of 3 FTE), while maturing a spinoff route. Hands-on experience in molecular biology and in vitro & in vivo PK/PD models (mice, hamster and sheep), global academic and corporate network. Lab Director: Prof. Paul Declerck. Supported by an IWT Spinoff Innovation Postdoc Mandate.
Postdoctoral Researcher - Antibody Gene Transfer Program
October 2013 --- May 2016
Developing an antibody gene-transfer platform for the in vivo production of therapeutic mAbs. Antibody gene transfer is at crossroads between mAb and gene therapy. Following delivery of the DNA that encodes a recombinant mAb of choice, this approach seeks to turn the site of delivery (muscle, tumor, skin) into a ‘bioreactor’, inducing prolonged mAb expression and secretion into circulation. By lowering the cost of goods and frequency of administration, this DNA-based approach represents an innovative alternative to the conventional production and delivery of mAb.
August 2011 --- September 2013
Gained hands-on experience in molecular biology, immunology/immunotherapy, in vitro and in vivo tumor research and drug discovery/development. Specific focus on immunotoxins, mechanisms of resistance, apoptotic pathways in pancreatic cancer and biomarkers. Findings supported clinical trials. Lab Director: Dr. Ira Pastan.
PhD Fellow in Medical Sciences
September 2008 --- June 2011
Subject: The role of blood protein biomarkers in the management of malignant pleural mesothelioma Evaluated the use of presumed blood protein biomarkers in the management of mesothelioma (diagnosis, screening, prognosis and monitoring therapy response) by executing/managing a Belgian multicenter study (600+ participants) and establishing international collaborations. Specific focus on the effect of patient characteristics on biomarker levels.
August 2007 --- June 2008
Study of the expression and methylation status of genes and microRNAs in neuroblastoma
ApproachabilityCollaborationCommunicativeCreative thinkingCuriosityOrganizationProactivityProblem solvingSelf-confidenceSelf-disciplineStrategic thinking
R&D Scientific writing Animal models Biostatistics NegotiationAntibodiesAssay developmentBiological Drug DevelopmentCancer ResearchCell CultureBiomedical SciencesBudget ManagementBusiness DevelopmentDiagnosticsDrug DeliveryEnzyme-linked immunosorbent assay (ELISA)
Postgraduate in Innovation and Entrepreneurship in Engineering from University of Leuven in 2017
Bachelor - Master in Bioscience Engineering in Cell and Gene Biotechnology from Ghent University in 2008
Master in Biotecnologia from Universidad Politécnica de Valencia in 2007
in Latin-Mathematics from Sint-Lodewijkscollege Bruges in 2003
Training and Certification
Laboratory Animal Science Certificate Certification